Breakpoint characterization of large deletions in EXT1 or EXT2 in 10 Multiple Osteochondromas families by Jennes, Ivy et al.
RESEARCH ARTICLE Open Access
Breakpoint characterization of large deletions in
EXT1 or EXT2 in 10 Multiple Osteochondromas
families
Ivy Jennes
1†, Danielle de Jong
2†, Kirsten Mees
1, Pancras CW Hogendoorn
3, Karoly Szuhai
2† and Wim Wuyts
1*†
Abstract
Background: Osteochondromas (cartilage-capped bone tumors) are by far the most commonly treated of all
primary benign bone tumors (50%). In 15% of cases, these tumors occur in the context of a hereditary syndrome
called multiple osteochondromas (MO), an autosomal dominant skeletal disorder characterized by the formation of
multiple cartilage-capped bone tumors at children’s metaphyses. MO is caused by various mutations in EXT1 or
EXT2, whereby large genomic deletions (single-or multi-exonic) are responsible for up to 8% of MO-cases.
Methods: Here we report on the first molecular characterization of ten large EXT1- and EXT2-deletions in MO-
patients. Deletions were initially indentified using MLPA or FISH analysis and were subsequently characterized using
an MO-specific tiling path array, allele-specific PCR-amplification and sequencing analysis.
Results: Within the set of ten large deletions, the deleted regions ranged from 2.7 to 260 kb. One EXT2 exon 8
deletion was found to be recurrent. All breakpoints were located outside the coding exons of EXT1 and EXT2. Non-
allelic homologous recombination (NAHR) mediated by Alu-sequences, microhomology mediated replication
dependent recombination (MMRDR) and non-homologous end-joining (NHEJ) were hypothesized as the causal
mechanisms in different deletions.
Conclusions: Molecular characterization of EXT1- and EXT2-deletion breakpoints in MO-patients indicates that
NAHR between Alu-sequences as well as NHEJ are causal and that the majority of these deletions are nonrecurring.
These observations emphasize once more the huge genetic variability which is characteristic for MO. To our
knowledge, this is the first study characterizing large genomic deletions in EXT1 and EXT2.
Keywords: Multiple osteochondromas, EXT1, EXT2, deletion breakpoint, arrayCGH, NAHR, NHEJ, MMRDR, bone
neoplasm
Background
Osteochondromas (cartilage-capped bone tumors) are by
far the most commonly treated of all primary benign
bone tumors (50%) [1]. Most osteochondromas appear
as solitary, nonhereditary lesions, but in 15% of cases
these tumors occur as multiple lesions in the context of
multiple osteochondromas (MO) [2] (OMIM 133700-
133701), previously known as osteocartilaginous exosto-
sis or multiple hereditary exostosis (MHE/HME). The
prevalence of this autosomal dominant skeletal disorder
is estimated to be 1/50.000 in the Western population
[3]. MO is characterized by the formation of multiple
osteochondromas mainly arising from the growth plate
area in the juxta-epiphyseal region of long tubular
bones. These bone neoplasmas are caused by an
increased chondrocyte proliferation and bone growth at
children’s metaphyses [4]. During the first decades of
life, they develop gradually and grow in size and num-
ber, until skeletal maturation is achieved at the end of
puberty with the closing of the growth plates [5]. MO is
characterized by a significant inter-and intrafamilial phe-
notypic variability, including variation in the number
and size of osteochondromas, the number and location
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Various complications arise from these benign tumors,
but malignant transformation towards a chondrosar-
coma is by far the most serious one, occurring in 0.5-2%
of patients [2,3,6].
MO is caused by mutations in Exostosin-1 (EXT1)
(OMIM *608177) [7] or Exostosin-2 (EXT2)( O M I M
*608210) [8,9]. EXT1 consists of 11 exons, is located at
8q24.11-q24.13 and spans ~350 kb [10], while EXT2,
located at 11p12-p11, comprises of 16 exons and span-
ning ~108 kb [11]. Both genes act as tumor suppressor
genes that belong to the EXT multigene family [12] and
are ubiquitously expressed. All members of this family
encode proteins that are involved in the adhesion and/
or polymerization of heparin sulphate (HS) chains at HS
proteoglycans (HSPG’s). The HSPG’s play a crucial role
in the diffusion of Indian Hedgehog (Ihh), which is
important for the regulation of chondrocyte proliferation
and differentiation. In osteochondromas, the cartilage
cells of the tumor cap are heterogeneous regarding to
the mutation status in EXT1 or EXT2, with a mixture of
homozygous and heterozygous EXT-inactivated cells
[13].
MO is characterized by a huge genetic heterogeneity.
The online Multiple Osteochondromas Mutation Data-
base (MOdb) http://medgen.ua.ac.be/LOVDv.2.0/home.
php provides an overview on all currently reported MO-
causing mutations. To date, the database contains more
than 1000 MO-patients representing more than 600
unique EXT1-o rEXT2-mutations. In 3.7% of the
MOdb-cases, the disease is caused by a large deletion
consisting of at least one EXT1- or EXT2-exon [14].
However, these rearrangements are expected to account
for up to 5-8% of MO cases [15,16].
Large genomic deletions can occur during the repair
of double strand breaks (DSB’s) in DNA by several
mechanisms [17], including non-homologous end-join-
ing (NHEJ) (including classical-and non-classical NHEJ),
microhomology-mediated replication-dependent recom-
bination (MMRDR) and homologous recombination
(HR) (including non-allelic homologous recombination
(NAHR) and single strand annealing (SSA)). Large dele-
tions containing EXT1 or EXT2 can result in contiguous
gene syndromes. The Tricho-Rhino-Phalangeal syn-
drome (TRPSII), also known as the Langer-Giedion syn-
drome (LGS), is caused by deletions in 8q24.11-q24.13,
including the EXT1 and TRPS1 genes, and is character-
ized by patients having MO and TRPSI characteristics
(facial dysmorphy, microcephaly, sparse scalp hair, short
stature and cone-shaped epiphyses) as well as mental
retardation [18,19]. The Potocki-Shaffer syndrome
(P11pDs or DEFECT11 syndrome) (OMIM 601224) is
caused by deletions in 11p11.2-p12, including the EXT2
and ALX4 genes, and is characterized by patients having
MO combined with Foramina Parietalia Permagna (FPP)
(OMIM 168500), mental retardation and craniofacial
dysotosis [20,21].
Smaller single or multi-exon rearrangements in EXT1
or EXT2 cause a phenotype of multiple osteochondro-
mas only. They are routinely screened for by Multiplex
Ligation-dependent Probe Amplification (MLPA) [16].
However, this diagnostic technique does not provide
detailed information on the breakpoints, so different
deletions involving the same exon(s) cannot be distin-
guished, nor can insight be acquired into the develop-
mental mechanism of these gross rearrangements.
Therefore, we characterized for the first time the MO-
causing genomic deletions in EXT1 or EXT2 in index
patients from ten unrelated families, using an MO-speci-
fic tiling path array, allele-specific PCR-amplification
and direct sequencing.
Methods
Patients
This study included index patients from ten unrelated
families (Family 89, 122, 150, 200, 250, 279, 300, 334,
338 and 361) originating from all over Europe and the
USA. The study was approved by the ethical committee
o ft h eU n i v e r s i t yo fA n t w e r pu n d e rn u m b e rA 0 4 - 6 4 .
Consent of the patients was obtained. All patients had
radiological confirmed multiple osteochondromas.
Genomic DNA was isolated from peripheral blood
according to standard procedures. Two patients were
reported to be sporadic cases while for six patients the
disease was reported to be inherited. Details on patients
are listed in Table 1.
All patients were selected from a larger cohort of MO
patients based on the presence of a single or multi exon
deletion in the EXT1 or EXT2 gene, detected by MLPA
analysis [16] or FISH analysis with EXT1-probes 46F10,
65G5 and 90D8 [7] or EXT2-probes A1151 and D0694
[9]. The MLPA/FISH findings on two of these families
(Families 150 and 200) have been reported previously
[16].
ArrayCGH tiling path array
High-resolution oligonucleotide arrayCGH analysis was
performed using a custom-made Agilent oligonucleo-
tide-based chip (Agilent Technologies, Santa Clara, CA,
USA) in accordance with manufacturers’ instructions.
This array contains ~44.000 probes and has a tiling cov-
erage for EXT1 and EXT2, additional genes involved in
HS-pathways and adjacent genes. This MO-specific til-
ing path array has been thoroughly described in [22].
PCR-amplification & sequencing
For the exact mapping of the deletion breakpoints,
allele specific PCR’s were designed around the deletion
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PCR-amplifications were performed by with a Touch
Down temperature protocol using Platinum Taq DNA
Polymerase (Invitrogen, San Diego, CA, USA) and the
Advantage UltraPure dNTP Combination Kit (Clon-
tech, Mountain View, CA, USA). Amplification pro-
ducts were subsequently sequenced using Big Dye
Terminator Cycle Sequencing kit with sequencing ana-
lysis on an ABI3130xl genetic analyzer (Applied Bio-
systems, Foster City, CA, USA). Primers for PCR-
amplification and sequencing analysis of breakpoints
are listed in Table 1.
In silico analysis of breakpoint regions
Sequences located 25 bp down-and upstream from the
breakpoints as well as the breakpoint region were ana-
lyzed for the presence of DNA-motifs (and their com-
plements) that are known to be associated with genomic
deletions, being translin target sites (ATGCAG,
GCCCWSSW), immunoglobulin heavy chain class
switch repeats (GAGCT, GGGCT, GGGGT, TGGGG,
TGAGC) and the deletion hotspot consensus sequence
(TGRRKM) [23]. The same regions were also analyzed
for purine-pyrimidine repeats. Finally, sequences 125 bp
down-and upstream from the breakpoint junctions were
analyzed for their AT-content.
Regions of 1 kb down-and upstream from the break-
point junctions were additionally analyzed for repeats
(Alu-elements and LINE’s) with the UCSC human gen-
ome browser http://genome.ucsc.edu.
In the search for homologous sequences, alignment of
sequences up to 10 kb down-and upstream from the
breakpoint junctions was performed using the NCBI
BLAST2-software http://www.ncbi.nlm.nih.gov/blast/
bl2seq/wblast2.cgi.
Results
Identification of deletion breakpoints with ArrayCGH,
PCR-amplification & sequencing
We subjected samples from the ten index patients with
heterozygous causal EXT1 or EXT2 deletions to tiling
path arrayCGH, allele-specific PCR-amplification and
sequencing analysis for characterization of the deletion
breakpoints. This allowed determination of the precise
size of the respective deletions and the position of the
proximal and distal breakpoints or breakpoint regions
for all ten patients. An overall view to scale on the
extend of all analyzed EXT1 and EXT2 d e l e t i o n si sp r o -
vided in Figure 1, while Table 2 summarizes sequences
flanking the deletions breakpoints.
In silico analysis of deletion breakpoints
An overview on all results on the presence of micro-
homologies at the breakpoint junctions, alternating pur-
ine-pyrimidine sequences and deletion-associated DNA
sequence motifs can be found in Table 2. Analysis of
the AT-percentages for the sequences located 125 bp
down-& upstream of proximal and distal breakpoints
showed AT-enriched regions (≥65%) on both break-
points for families 338 and 279.
A schematic illustration on all recombination events
can be found in Figure 2, including the BLAST2 results
c o n c e r n i n gh o m o l o g o u sr e g i o n sa sw e l la st h eU C S C
results concerning the presence of Alu-and LINE1-ele-
ments. Only the 2 kb regions around the breakpoints
are represented. No other homologies that could have
Table 1 Overview on the characteristics of 10 MO-families
Family
number
Patient
number
Disease
occurrence
Geographic
origin
Deletion at exon-
level
Forward PCR-primer Reverse PCR-primer
EXT1
89 54782 Familial USA exon 2-11 GGGCAAAATTGTCCTCTGTC TTGGTTGAGAGCCCAGATTT
200 73585 Familial Spain exon 8 CCCCACACACACACACTACA TCAAATGCATAAACTCACTTCTGA
250 74559 Familial USA exon 2-3 CGGGAGAGAGAAACCATGAA TGAGAGGGGAAAAACACCAG
300 86255 Familial - exon 6-7 CCAAACCTGTTATGGGAACC GATTTTCCCCCAGATGGTGT
338 91636 De novo Bulgaria exon 11 TCATTATGTGGTGCATGACTG CCTTTATGAAAGGCCACCAG
361 94668 - Denmark exon 2-11 GTTGACTGGTCCCACTGGTT TGTCTTCCCAATCCTGTTTCA
EXT2
122 59931 Familial Spain exon 8 CCCATTGCCTTTGCATTACT TGACTCCTCATGCAACCAAA
334 91391 De novo Bulgaria exon 8 CCCATTGCCTTTGCATTACT TGACTCCTCATGCAACCAAA
150 60859 Familial USA exon 2 ATGCAGGATGCCAAAATA CCCAACAGCACATCAGACAC
279 84389 Familial Macedonia exon 8 GGATGGAAATGTGGGATAAGG CACACCACCAGGGTTAATGC
Overview on the disease occurrence, the geographic origin as well as the deletion at exon-level. Patient numbers were provided together with MO-family
numbers, so additional information on our patients can be accessed in the MOdb http://medgen.ua.ac.be/LOVDv.2.0/home.php. Additionally, primers for allele-
specific PCR-amplification of the deletion breakpoint are listed.
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identified outside these regions.
Discussion
The most prominent DNA-repair mechanism in human
cells is NHEJ, involving simple ligation of any two DSB’s
in the absence of extensive sequence homology. NHEJ is
divided into two sub-pathways, classical and non-classi-
cal. In classical NHEJ, end-resection is very limited since
this pathway only efficiently joins DSB’sw i t ho v e r h a n g s
of fewer than four bases. Typical for this mutation
mechanism is that it can be facilitated by terminal
microhomologies (1-4 bp), although their presence is
not necessary [24]. In non-classical NHEJ or “microho-
mology-mediated end joining” (MMEJ) however, a rare
end-joining event takes place which uses longer micro-
homology regions (5-25 bases) [25]. Non-classical NHEJ
can also repair ends of a single DSB in a way similar to
SSA, resulting in the generation of small-scale deletions
[26].
MMRDR comprises all replication-based mutational
models that are predicated upon the use of microhomol-
ogy for strand misaligning. NHEJ-compatible events
involving microhomologies can be explained either by
NHEJ or by MMRDR, implicating that both mechanisms
do not necessarily rule each other out [17].
Homologous recombination is the second major repair
pathway for DSB’s. It uses a homologous sequence as a
template for repair. However, erroneous recombination
on a non-allelic homologous site can lead to chromoso-
mal rearrangements, including deletions. The different
submechanisms depend on the homologous sequence
that is used. NAHR or “unequal HR” represents the
main homologous recombination mechanism. It is the
Figure 1 To scale overview on the extend of all analyzed deletions. A.) Deletions in EXT1, B.) Deletions in EXT2.
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Gene Family
number
Deletion
size
(bp)
Position
breakpoints
Breakpoint sequences DNA sequence motifs
EXT1 89 259.450 Proximal:
118.829.422-118.829.425
Distal:
119.088.871-119.088.874
ATTTTCCTTGAAAGGAGGCCTCTAGTTTTC|accaagttatcaaaaatattcaaga–
–catcttccacccatttggatggattttttc|CTGTTCTCAGAAGCTGGGTTTGACC
TATTCA:
Deletion hotspot consensus sequence
(complement)
EXT1 200 5885 Proximal:
118.891.184-118.891.186
Distal:
118.897.068-118.897.070
ACAGGCGGGAGCCACTGTACCTGGCCAA|cattgttgttcgttttaaaggagtt–
–ggtgtaggtaatcacaacctaatttcaa|TTTTCTAGCAGATGCTCACCATCCC
GCTCA:
Immuno heavy chain class swith repeat
(complement)
EXT1 250 148.254 Proximal:
118.914.819-118.914.854
Distal:
119.063.074-119.063.109
TTTTTTTAGTAGAACTGGGGTTTCGCCATGTTGGCCAGGCTGGTCTTGAACTCCTGACCTC|
aagtgatctgcctgccttggcctcc–
–tatttttagtagagatggtgtttcaccatgttggccaggctggtcttgaactcctgacctc|
GTGATCCACCTGCCTCAGCCTCCCA
TGGGG:
Immuno heavy chain class swith repeat
GGGGT:
Immuno heavy chain class swith repeat
GATCCA:
Deletion hotspot consensus sequence
(complement)
GCCTCA:
Deletion hotspot consensus sequence
(complement)
EXT1 300 6176 Proximal:
118.896.107-118.896.110
Distal:
118.902.282-118.902.285
CTCACATACTTTTTTTCTCAGCTATATCA|ctgctacacgaagaagagattctgg–
–caggtgtgaattcagagaggatgtcatca |TCCTTACTATAACTTCTGGAAGAAG
-
EXT1 338 5688 Proximal:
118.877.923-118.877.925
Distal:
118.883.610-118.883.612
ATTCTACCAAACAGTATTTCTAGTAATT|catacatctttaacaaaaaaatcta–
–attacagtaggctatgttagcctttatt| TTGGTGGTTCTCAAATACCTGGTGA
-
EXT1 361 205.798 Proximal:
118.805.191-118.805.193
Distal:
119.010.988-119.010.990
AAATCTATTGAGCCTGCTTATGATTCTTT|ggttttggaggaggagggcactaat–
–ttgttttgttttgttttgttttttgcttt| TCTGAGATGGAGTTTTGCTCTCGTT
TGAGC:
Immuno heavy chain class swith repeat
AGGAGGGC:
Translin binding site (complement)
EXT2 122, 334 8690 Proximal:
44.143.251-44.143.282
Distal:
44.151.940 - 44.151.971
GATCTCCTGACCTCGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGG|
cgtgagccaccgcgcccggcccaca–
–catctcctgatcttgtgatccgcctgcctcggcctcccaaagtgctgggattacagg|
TGTGAGCCACCGCGCCCGGCCTTTT
TGAGC:
Immuno heavy chain class swith repeat
TGAGC:
Immuno heavy chain class swith repeat
EXT2 150 2749 Proximal:
44.084.367-44.084.368
Distal:
44.087.115 - 44.087.116
ATGCAAATTCAGGGATGGAAAGAACTG|ttggtgttcgtctttgtaaatgaat–
–gaagcaggtctgtatgggacaagcttg|AAGTACACGTGCGTTCATTTTTCCC
-
EXT2 279 41.025 Proximal:
44.130.050
Distal:
44.171.074
TTTGGCCATTCTAATAGATATGTAT|ttgtatcttattgctgttttaattt–
–gctattcatatctatacataagggg|GACTGATAAAACAGGCCTGAGTCAT
TATTCA:
Deletion hotspot consensus sequence
(complement)
TGAGTC:
Deletion hotspot consensus sequence
The positions of the proximal and distal breakpoints or breakpoint regions were given according to the UCSC Human Genome Browser assembly from March 2006 (NCBI36/hg18) on the respective chromosomes (the
reverse strand of chromosome 8 for EXT1 and the forward strand of chromosome 11 for EXT2). Breakpoint sequences were given, including 25 bp down-and upstream from the breakpoints or breakpoint regions if
homologous sequences (marked in grey) were present at the breakpoints. Down-and upstream borders of the deleted sequences are indicated in small characters. Alternating purine-pyrimidine sequences are
underlined. Finally, DNA sequence motifs associated with deletions are marked in bold, while the motif sequence and the deletion-associated motif type can be found in the last column.
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9Figure 2 Schematic representation on all deletions. The curved line represents the DNA sequence, with in black the non-deleted sequence
and in grey the deleted part, including the deleted exons that are represented by grey blocks. The upper and lower horizontal lines represent
the 20 kb regions around each deletion breakpoint and are to scale. The middle line, including the deleted exons, is not to scale. Vertical black
lines point at the deletion breakpoints. Alu-elements are indicated by red bars, LINE1-elements by blue bars. Sequence homology at the
deletions breakpoints is mentioned in the arrow, representing the deletion. A.) Family 89 (EXT1 exon 2-11 deletion), B.) Family 200 (EXT1 exon 8
deletion), C.) Family 250 (EXT1 exon 2-3 deletion), D.) Family 300 (EXT1 exon 6-7 deletion), E.) Family 338 (EXT1 exon 11 deletion), F.) Family 361
(EXT1 exon 2-11 deletion), G.) Families 122 & 334 (EXT2 exon 8 deletion), H.) Family 150 (EXT2 exon 2 deletion), I.) Family 279 (EXT2 exon 8
deletion).
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most common mechanism underlying disease-associated
genomic rearrangements. It occurs between two non-
allelic homologous sequences, generally with a length of
at least 200 bp, often consisting of repetitive elements
such as long or short interspersed nuclear element
(LINE’so rS I N E ’si n c l u d i n gAlu-elements) or low copy
repeats (LCR’s). A second HR-mechanism is SSA, which
can take place when DSB’s are flanked by direct repeats.
This pathway uses these repeat sequences as the identi-
cal sequences that HR needs for repair, instead of
requiring the presence of a homologous sequence. After
5’-end resection, the 3’-tails simply anneal to each other
before one of the 3’-tails can find and base-pair with a
homologous sequence. SSA results in simple rearrange-
ments with deletion of the DNA-fragment located
between the repeats as well as one of both repeats.
Since the success rate of this pathway is inversely related
to the distance separating the direct repeats (SSA
depends on the formation of a short hairpin loop
between breakpoint ends), SSA only accounts for small-
scale deletions [27,28].
So, it is clear that gross genetic deletions do not
appear randomly in the genome. They are associated
with DNA-sequences promoting either one of the above
mentioned mutation mechanisms. Additional features
that have been shown to play a role in the appearance
of large deletions, are sequences rich in adenine and
thymine (AT-enriched sequences), alternating purine-
pyrimidine repeats and recombination-associated motifs
such as translin binding sites, immunoglobulin heavy
chain class switch sites and deletion hotspot consensus
sequences [23].
To date, single or multi-exon rearrangements in EXT1
or EXT2 have been routinely screened for by Multiplex
Ligation-dependent Probe Amplification (MLPA) [16].
However, since this diagnostic technique does not pro-
vide insight into the developmental mechanism of these
rearrangements, we characterized for the first time the
large genomic deletions in EXT1 and EXT2 in index
patients from ten unrelated families using sequencing
analysis and hypothesized on the developmental
mechanism of these rearrangements.
Recent studies have demonstrated that high content of
Alu-elements results in increased frequency of gene dis-
ruption by large deletions in several human diseases
[29]. Alu-elements are by far the most abundant short
interspersed nuclear element (SINE’s), with an estimated
copy number of ~1.4 million [30,31]. They are con-
served repeats with a consensus sequence of ~300 bp
that have been amplified in primate genomes through
retroposition [32] and consist of different subfamilies
(AluY, AluSx, ...) (reviewed in [33]). These elements
have been proposed to have a number of functions in
the human genome, but it is certain that they did have a
major impact on genomic architecture, since dispersion
of the Alu-sequences throughout the genome offers
many opportunities for NAHR [34,35], leading to Alu-
recombination mediated deletion (ARMD)-events
[36,37]. LINE1-elements, a subgroup of the long inter-
spersed nuclear elements (LINE’s) are also known to fre-
quently provide sequence homology for NAHR.
Consequently, we analyzed the whole genomic
sequences of EXT1 and EXT2 for the presence of these
elements. The EXT1 genomic region was found to be
enriched in Alu-elements (13.4% compared to 10.6% in
the human genome), while the EXT2 region showed to
be rich in LINE1-elements (20.4% compared to 16.9% in
the human genome) [38]. This might explain why both
genes are more prone to deletions.
In the EXT1 exon 2-3 deletion of family 250 as well as
in the EXT2 exon 8 deletion of unrelated families 122
(Spain, familial MO) and 334 (Bulgaria, de novo MO)
extensive sequence similarity was identified between the
breakpoint regions. These rearrangements were shown
to be caused by recombination between Alu-repeats,
giving rise to the formation of a novel complete recom-
binant Alu-sequence. We concluded these deletions to
be caused by NAHR, with this hypothesis further sup-
ported by the fact that the EXT2 exon 8 deletion was
recurrent. Additionally, these deletion-causing recombi-
nations might have been facilitated by the presence of
multiple deletion-associated DNA sequence motifs.
For family 200 and 279, no homology was found at
the breakpoints of the respective EXT1 exon 8 deletion
and the EXT2 exon 8, although multiple LINE1-and
Alu-elements were identified in the proximity of the
breakpoints as well as multiple deletion-associated DNA
sequence motifs. Consequently, these cases were found
to be consistent with the classical NHEJ mutation
mechanism.
For family 89, the breakpoints of the EXT1 exon 2-11
deletion were located within a 5-bp homologous
sequence. Multiple LINE1-and Alu-elements were iden-
tified at the distal breakpoint, while the proximal break-
point only showed the presence of the complement of a
deletion hotspot consensus sequence. The 5 bp-micro-
homology at the breakpoint junctions implied that this
deletion was probably caused by non-classical NHEJ or
by MMRDR.
For the remaining 4 families (Family 300 with EXT1
exon 6-7 deletion, Family 338 with EXT1 exon 11 dele-
tion, Family 361 with EXT1 exon 2-11 deletion, Family
150 with EXT2 exon 2 deletion), deletion breakpoints
were located within microhomologies (2-4 bp), consis-
tent with either the classical NHEJ or the MMRDR
mechanism. Alu-elements were found in the proximity
of all breakpoint regions, except for the distal
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while deletion-associated motifs were found at the prox-
imal breakpoint of the EXT1 exon 2-11 deletion from
family 362.
In our series, only two patients harbored an identical
deletion (EXT2 - exon 8 deletion). In MO, the size and
location of the various intragenic EXT deletions does not
seem to correlate with phenotypical differences as all these
deletions are assumed to cause loss-of-function of the
respective tumor suppressor gene EXT1 or EXT2.T h e
same is true for EXT loss of function point mutations,
where no intragenic genotype-phenotype correlation is
observed [16]. The only correlation that can be observed is
for larger deletions causing the contiguous gene syn-
dromes Langer Giedion syndrome [19] and Proximal 11p
Deletion syndrome (Potocki-Shafer syndrome) [20,21], but
such patients were not included in our series. Further-
more, our patient dataset was too small to confirm pre-
vious observations of EXT1 patients being more severely
affected compared to EXT2 patients [16].
The identification of the breakpoints of this subset of
patients makes it possible to design allele specific PCR-
assays allowing targeted screening for recurrent dele-
tions. Performing these allele specific PCR-amplifica-
tions on a larger set of EXT-deletion patients can
further confirm the absence or presence of deletion hot
spots for MO-causing single-or multi-exon deletions in
EXT1 and EXT2.
Conclusions
Out of the ten deletions analyzed in this study, NAHR
was found to be the causal mechanism in two cases.
Two deletions were caused by classical NHEJ, while four
other rearrangement events could be explained by either
classical NHEJ or MMRDR. Finally, non-classical NHEJ
or MMRDR were the possible mutation mechanisms for
the last deletion. One deletion, typically caused by
NAHR, was shown to be recurrent in 2 patients, but no
clear deletion breakpoint hotspots could be identified
within our set of patients.
So, we can conclude that MO-causing large genomic
deletions in EXT1 or EXT2 are caused by a variety of
mutation mechanisms, emphasizing once more the huge
genetic variability for MO.
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